Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience
Oren Pasvolsky,Sassine Ghanem,Denái R. Milton,Mikael Rauf,Mark R. Tanner,Qaiser Bashir,Samer Srour,Neeraj Saini,Paul Lin,Jeremy Ramdial,Yago Nieto,Guilin Tang,Yosra Aljawai,Hina N. Khan,Partow Kebriaei,Hans C. Lee,Krina K. Patel,Sheeba K. Thomas,Donna M. Weber,Robert Z. Orlowski,Elizabeth J. Shpall,Richard E. Champlin,Muzaffar H. Qazilbash
DOI: https://doi.org/10.1038/s41408-023-00973-w
IF: 9.812
2024-01-11
Blood Cancer Journal
Abstract:The prognostic impact of additional copies of chromosome 1q (1q + ) on outcomes of newly-diagnosed multiple myeloma (NDMM) patients undergoing autologous transplantation (autoSCT) is unclear. We conducted a retrospective single-center analysis of NDMM patients with 1q21 gain/amplification (3 or ≥4 copies of 1q, respectively) that received autoSCT between 2008–2018. 213 patients were included (79% 1q gain; 21% 1q amplification). The most commonly used induction regimen was bortezomib, lenalidomide, and dexamethasone (41%). At day100 post-autoSCT and at best post-transplant response, 78% and 87% of patients achieved ≥VGPR, and 38% and 50% achieved MRD-negative ≥VGPR, respectively. Median PFS and OS for the entire cohort were 35.5 months and 81.4 months, respectively. On multivariable assessment for PFS, MRD negative ≥VGPR before autoSCT (HR 0.52, p = 0.013) was associated with superior PFS, whereas 1q amplification was associated with inferior PFS (2.03, p = 0.003). On multivariate analysis for OS, achieving MRD negative ≥VGPR at best post-transplant response was associated with superior survival (0.29, p < 0.001), whereas R-ISS III and concomitant del17p or t(4:14) were associated with inferior survival (6.95, p = 0.030, 2.33, p = 0.023 and 3.00, p = 0.047, respectively). In conclusion, patients with 1q+ NDMM, especially 1q amplification, have inferior survival outcomes compared to standard-risk disease after upfront autoSCT, though outcomes are better than other high-risk cytogenetic abnormalities.
oncology,hematology